title: [Liposome formulations of combretastatin A4 and 4-arylcoumarin analog prodrugs: antitumor effect in the mouse model of breast cancer].
abstract: The antimitotic agent combretastatin A4 (CA-4) has been suggested as an antivascular agent for anticancer therapy relatively recently. To reduce systemic toxicity by means of administration in liposome formulations, in this study new lipophilic prodrugs, oleic derivatives of CA-4 and its 4-arylcoumarin analog (CA4-Ole and ArC-Ole, respectively), have been synthesized: Liposomes of 100 nm mean diameter prepared on the basis of egg phosphatidylcholine and phosphatidylinositol from bakers yeast have been shown to include completely up to 10 mol. % of CA4-Ole, or 7 mol. % of ArC-Ole. Also, prodrug bearing liposomes decorated with tetrasaccharide selectin ligand Sialyl Lewis X (SiaLe(x)) have been constructed to achieve targeting to endothelium under neovascularization. The antitumor activity in vivo was studied in the model of slowly growing mouse breast cancer. Under the used dose (22 mg/kg) as well as the regimen of treatment (four injections, one per a week, starting from the appearance of palpable tumors) cytostatic CA-4 did not reveal any anticancer effect, and oppositely even stimulated tumor growth. Liposome formulations of CA4-Ole did not show such stimulation. However, to achieve pronounced antitumor effect, number of injections of liposomes should be apparently elevated. New antimitotic agent ArC revealed cytotoxic activity of only one tenth value obtained for CA-4 in vitro in the culture of human breast carcinoma cells. Nevertheless, in vivo in the mouse model of breast cancer this compound showed antitumor effect under double CA-4 equivalent dose. The results demonstrate availability of SiaLe(x)-liposomes loaded with ArC-Ole: this preparation began to inhibit tumor growth already after the second injection. It is necessary further to choose doses and regimens of administration both for ArC and liposome formulations bearing ArC-Ole.
authors.forename: E V
authors.initials: EV
authors.lastname: Mouseeva
authors.forename: N R
authors.initials: NR
authors.lastname: Kuznetsova
authors.forename: E V
authors.initials: EV
authors.lastname: Svirshchevskaia
authors.forename: N V
authors.initials: NV
authors.lastname: Bovin
authors.forename: N C
authors.initials: NC
authors.lastname: Sitnikov
authors.forename: A S
authors.initials: AS
authors.lastname: Shavyrin
authors.forename: I P
authors.initials: IP
authors.lastname: Beletskaia
authors.forename: S
authors.initials: S
authors.lastname: Combes
authors.forename: A Iu
authors.initials: AIu
authors.lastname: Fedorov
authors.forename: E L
authors.initials: EL
authors.lastname: Vodovozova
mesh_terms: D000818:Animals; D050256:Antimitotic Agents / Q000008:administration & dosage / Q000494:pharmacology; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000494:pharmacology; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology; D045744:Cell Line, Tumor; D003374:Coumarins / Q000008:administration & dosage / Q000138:chemical synthesis* / Q000494:pharmacology; D004334:Drug Administration Schedule; D004354:Drug Screening Assays, Antitumor; D005260:Female; D006801:Humans; D008081:Liposomes / Q000008:administration & dosage*; D051379:Mice; D008810:Mice, Inbred C57BL; D009844:Oligosaccharides / Q000737:chemistry; D011355:Prodrugs / Q000008:administration & dosage / Q000138:chemical synthesis* / Q000494:pharmacology; D000080506:Sialyl Lewis X Antigen; D013267:Stilbenes / Q000008:administration & dosage / Q000138:chemical synthesis* / Q000494:pharmacology
chemical_list: D050256:Antimitotic Agents; D000972:Antineoplastic Agents, Phytogenic; D003374:Coumarins; D008081:Liposomes; D009844:Oligosaccharides; D011355:Prodrugs; D000080506:Sialyl Lewis X Antigen; D013267:Stilbenes; C058728:fosbretabulin